Evidence map›Paper›PMID 27815373›Full record

ArticleCirculation2017

Inhibiting Insulin-Mediated β2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction.

Qingtong Wang, Yongming Liu, Qin Fu, Bing Xu, Yuan Zhang, Sungjin Kim, Ruensern Tan, Federica Barbagallo, Toni West, Ethan Anderson and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Differential Downregulation of βJournal of the American Heart Association · 2024
    Article
  10. Review
  11. Review
  12. Article
  13. The βAdvances in pharmacological and pharmaceutical sciences · 2024
    Review
  14. Article
  15. Article
  16. βTrends in molecular medicine · 2023
    Article
  17. Article
  18. Review
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Qingtong Wang *Department of Pharmacology, University of California at Davis, CA 95616, USA.
Yongming Liu *Department of Pharmacology, University of California at Davis, CA 95616, USA.
Qin Fu *Department of Pharmacology, University of California at Davis, CA 95616, USA.
Bing XuDepartment of Pharmacology, University of California at Davis, CA 95616, USA.
Yuan ZhangDepartment of Medicine, Division of Endocrinology and Metabolism and Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA 52242, USA.
Sungjin KimDepartment of Pharmacology, University of California at Davis, CA 95616, USA.
Ruensern TanDepartment of Pharmacology, University of California at Davis, CA 95616, USA.
Federica BarbagalloDepartment of Pharmacology, University of California at Davis, CA 95616, USA.
Toni WestDepartment of Pharmacology, University of California at Davis, CA 95616, USA.
Ethan AndersonDepartment of Pharmacology and Toxicology, East Carolina University, Greenville, NC 27834, USA.
Wei WeiInstitute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Hefei, 230032, China.
E Dale AbelDepartment of Medicine, Division of Endocrinology and Metabolism and Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA 52242, USA.
Yang K XiangDepartment of Pharmacology, University of California at Davis, CA 95616, USA.
Shanghai University of Traditional Chinese Medicine · CNHuazhong University of Science and Technology · CNEast Carolina University · USUniversity of Iowa · USFraternal Order of Eagles · USShuguang Hospital · CN

Funding

Insulin Inhibition of beta-AR Signaling in the MyocardiumR01HL127764 · NHLBI · UNIVERSITY OF IOWA · PI ABEL, E DALE, XIANG, YANG K · 2015 to 2018
$2.4M
Myocardial redox status, catecholamine metabolism and post-operative arrhythmiaR01HL122863 · NHLBI · UNIVERSITY OF IOWA · PI ANDERSON, ETHAN JOHN · 2014 to 2018
$2.1M
Cardiac Dysfunction in the Met Syndrome: Cross-talk between IR and bAR SignalingR01HL112413 · NHLBI · UNIVERSITY OF IOWA · PI ABEL, E DALE, XIANG, YANG K · 2015 to 2018
$1.6M
Insulin Signaling and the Heart in DiabetesR01DK092065 · NIDDK · UNIVERSITY OF UTAH · PI ABEL, E DALE · 2010 to 2011
$649k
In Vivo Ultrasound Imaging System (VEVO 2100, VisualSonics)S10OD010389 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHIAMVIMONVAT, NIPAVAN · 2013 to 2013
$397k
Molecular mechanisms of Insulin resistance under chronic stressI01BX002900 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI XIANG, YANG K · 2016 to 2021
–
BLRD VA I01 BX002900NHLBI NIH HHS R01 HL112413NHLBI NIH HHS R01 HL122863NHLBI NIH HHS R01 HL127764NIDDK NIH HHS R01 DK092065NIH HHS S10 OD010389
6 · The paper itself

Abstract

backgroundType 2 diabetes mellitus (DM) and obesity independently increase the risk of heart failure by incompletely understood mechanisms. We propose that hyperinsulinemia might promote adverse consequences in the hearts of subjects with type-2 DM and obesity.

methodsHigh-fat diet feeding was used to induce obesity and DM in wild-type mice or mice lacking β

resultsHigh-fat diet feeding selectively increases the expression of phosphodiesterase 4D (PDE4D) in mouse hearts, in concert with reduced protein kinase A phosphorylation of phospholamban, which contributes to systolic and diastolic dysfunction. The expression of PDE4D is also elevated in human hearts with DM. The induction of PDE4D expression is mediated by an insulin receptor, insulin receptor substrate, and GRK2 and β-arrestin2-dependent transactivation of a β

conclusionsThese studies elucidate a novel mechanism by which hyperinsulinemia contributes to heart failure by increasing PDE4D expression and identify β

Indexed as

Animalsbeta-Arrestin 2CarbazolesCarvedilolCells, CulturedCyclic Nucleotide Phosphodiesterases, Type 4Diabetes Mellitus, Type 2Diet, High-FatExtracellular Signal-Regulated MAP KinasesG-Protein-Coupled Receptor Kinase 2Heart FailureHumansMaleMiceMice, Inbred C57BLMice, Knockoutbeta-Arrestin 2CarbazolesCarvedilolCyclic Nucleotide Phosphodiesterases, Type 4Extracellular Signal-Regulated MAP KinasesG-Protein-Coupled Receptor Kinase 2PropanolaminesReceptors, Adrenergic, beta-2Vasodilator Agentsdiabetic cardiomyopathyheart failureinsulinphosphodiesteraseβ-adrenergic receptors

Identifiers

PMID27815373
PMCPMC5302024
OpenAlexW2577306510

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.